Cancer Models

Challenging Cancer Heterogeneity with Reproducible and Predictive Preclinical Studies 

Pain Therapeutics

Translating Success from Preclinical Assays to the Clinic 

Early Drug Delivery

Improving Solubility and Bioavailability with Enabling Technologies 

Predictive Drug Safety

Predicting Drug-Induced Organ Toxicities Using Functional Assays, Models and Markers 

Preclinical Imaging

Integrating Molecular Imaging Technologies to Improve Preclinical Findings 

Plenary Keynote Panel Discussion
Advancing Pharma R&D through Communication & Collaborations: Bio-Connectivity at Work

Moderator:

J. Rick Turner, PhD, PGCE, Senior Scientific Director, Clinical Communications, Quintiles & Fellow, Society of Behavioral Medicine

Panelists:

Karim Dabbagh, Ph.D., Executive Director and Head, External R&D and Innovation Research Units, Pfizer Worldwide R&D

Glen N. Gaulton, Ph.D., Professor, Pathology and Laboratory Medicine; Executive Vice Dean and Chief Scientific Officer, Perelman School of Medicine, University of Pennsylvania

Peter Pitts, President and Co-Founder, Center for Medicine in the Public Interest

Short Courses

Addressing Safety Concerns for Biologics and Biosimilars 

Utilization of Cardiac Contractility Assays for Preclinical Safety Testing 

Animal Models of Pain: Progress and Challenges 

Design and Interpretation of Stability Studies for Product Development 

Use of Stem Cells for Safety Screening 

Introduction to Drug Metabolism and Its Role in Drug Toxicity 

Epigenetic Mechanisms of Pain 

Development of Nanotechnology Application into Innovative Therapies 

Roadmap for Outsourcing of Preclinical Imaging 

Advances in Imaging Quantitation 

Genetically Engineered Mouse Models versus Patient-Derived Xenograft Models: Comparing Strengths and Limitations